In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-faecalis and Non-faecium Enterococcal Isolates With/Without VanC Phenotype : Clinical Implications for Infective Endocarditis
García-González, Javier (Universitat de Barcelona)
Cañas, María A. (Universitat de Barcelona)
Cuervo, Guillermo (Instituto de Salud Carlos III)
Hernández-Meneses, Marta (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Verdejo, Miguel Ángel (Universitat de Barcelona)
Bodro, Marta (Instituto de Salud Carlos III)
Díez de los Ríos, Javier (Hospital Universitari de Vic)
Gasch Blasi, Oriol (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Ribera, Albert (Hospital de Barcelona)
Falces, Carles (Universitat de Barcelona)
Perissinotti, Andrés (Instituto de Salud Carlos III)
Vidal, Bárbara (Universitat de Barcelona)
Quintana, Eduard (Universitat de Barcelona)
Moreno, Asunción (Universitat de Barcelona)
Piquet, Maria (Universitat de Barcelona)
Roca, Ignasi (Universitat de Barcelona)
Fernandez-Pittol, Mariana (Universitat de Barcelona)
San José-Villar, Sol M. (Universitat de Barcelona)
García-de-la-Mària, Cristina (Universitat de Barcelona)
Miró, José M. (Instituto de Salud Carlos III)

Date:	2024
Abstract:	(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-faecalis/non-faecium enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in IE cases. (2) Methods: Time-kill curves with standard (ISI) and high (IHI) inocula were performed to test VanC isolates [3 E. casseliflavus (ECAS) and 1 E. gallinarum (EGALL)] and non-VanC isolates [1 E. durans (EDUR), 1 E. hirae (EHIR) and 1 E. raffinosus (ERAF)]. The narrative literature review of IE cases treated with AMP + CTR was analyzed alongside three study cases. Clinical outcomes were relapse and death. (3) Results: Ampicillin plus gentamicin (AMP + GEN) showed synergistic and bactericidal activity against most isolates. AMP + CTR was synergistic at ISI for EGALL, EDUR, and EHIR and bactericidal against EHIR. At IHI, indifferent activity was observed for all isolates. In IE cases treated with AMP + CTR, it was only effective for EDUR and EHIR. Clinical information for EGALL IE is lacking. For IE caused by ECAS and ERAF, AMP + CTR seems suboptimal or ineffective, respectively. (4) AMP + CTR cannot be recommended for treating IE due to ECAS/ERAF. In contrast, this combination was effective in IE caused by EDUR/EHIR and could be recommended.
Grants:	Instituto de Salud Carlos III PI17/01251 Instituto de Salud Carlos III PI20/00830 Ministerio de Sanidad y Consumo RD06/0008 Agencia Estatal de Investigación PID2021-127402OB-I00
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Enterococcal endocarditis ; E. casseliflavus ; E. durans ; E. gallinarum ; E. hirae ; E. raffinosus ; In vitro study ; Synergy ; Time-kill curves
Published in:	Microorganisms, Vol. 12 Núm. 12 (december 2024) , p. 2511, ISSN 2076-2607

DOI: 10.3390/microorganisms12122511
PMID: 39770714

16 p, 2.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles